Characteristics and Vaccine Booster Effectiveness in Covid-19 Infections Using 15 Days Post-Booster Period as Baseline during the Omicron Wave in A General Medicine office in Toledo (Spain)

J. Luis Turabián
{"title":"Characteristics and Vaccine Booster Effectiveness in Covid-19 Infections Using 15 Days Post-Booster Period as Baseline during the Omicron Wave in A General Medicine office in Toledo (Spain)","authors":"J. Luis Turabián","doi":"10.31579/2639-4162/050","DOIUrl":null,"url":null,"abstract":"Background: Vaccine covid-19 booster effectiveness (VBE) timing is not clearly known Objective: To compare the cases of covid-19 in vaccinated booster people with a time of <15 days vs. >= 15 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective study of adult patients with covid-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave. Results: Forty-six cases were included, 15 cases of Covid-19 breakthrough infections with booster shot <15 days (33%) with a mean time in days from booster to diagnostic covid-19 of 6 days, and 31 cases with booster > = 15 days (67%) with a time in days from booster to covid-19 diagnostic of 37 days of mean. Relative VBE <15 days (cases where it can be considered that the booster is not yet effective) vs. > = 15 days (cases where it can be considered that the booster is already effective) [1 - (Cases with vaccine Booster shot < 15 days) / (Cases with vaccine Booster shot > = 15 days) x 100] was 60%. Covid-19 cases with booster shot <15 days had been more vaccinated with 2 doses of ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford / AstraZeneca) plus booster of mRNA-1273 vaccine (Spikevax, formerly covid-19 Vaccine Moderna). Conclusion: In the general practice setting in Toledo, Spain, from December 1, 2021 to February 28, 2022, at the peak of omicron infections, booster after a period of <15 days provided 60% relative protection against symptomatic disease vs. > = 15 days. The results suggest that booster received <15 days provided early protection against SARS-CoV-2 infection of symptomatic Covid-19 of 60%. However, this result does not seem logical: this lower early risk may be transient and due to “vaccinated bias.”","PeriodicalId":93288,"journal":{"name":"General medicine and clinical practice","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General medicine and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2639-4162/050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vaccine covid-19 booster effectiveness (VBE) timing is not clearly known Objective: To compare the cases of covid-19 in vaccinated booster people with a time of <15 days vs. >= 15 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective study of adult patients with covid-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave. Results: Forty-six cases were included, 15 cases of Covid-19 breakthrough infections with booster shot <15 days (33%) with a mean time in days from booster to diagnostic covid-19 of 6 days, and 31 cases with booster > = 15 days (67%) with a time in days from booster to covid-19 diagnostic of 37 days of mean. Relative VBE <15 days (cases where it can be considered that the booster is not yet effective) vs. > = 15 days (cases where it can be considered that the booster is already effective) [1 - (Cases with vaccine Booster shot < 15 days) / (Cases with vaccine Booster shot > = 15 days) x 100] was 60%. Covid-19 cases with booster shot <15 days had been more vaccinated with 2 doses of ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford / AstraZeneca) plus booster of mRNA-1273 vaccine (Spikevax, formerly covid-19 Vaccine Moderna). Conclusion: In the general practice setting in Toledo, Spain, from December 1, 2021 to February 28, 2022, at the peak of omicron infections, booster after a period of <15 days provided 60% relative protection against symptomatic disease vs. > = 15 days. The results suggest that booster received <15 days provided early protection against SARS-CoV-2 infection of symptomatic Covid-19 of 60%. However, this result does not seem logical: this lower early risk may be transient and due to “vaccinated bias.”
以欧米克隆波后15天为基线,托莱多(西班牙)一家全科医院Covid-19感染的特点和疫苗强化效果
背景:新冠肺炎疫苗加强针有效性(VBE)时间尚不清楚目的:比较从加强针到感染诊断时间为=15天的接种加强针人群中的新冠肺炎病例,并评估其相对VBE。方法:2021年12月至2022年2月期间,在奥密克戎变异株传染波期间,对接种加强针的人群中新冠肺炎突破性感染的成年患者进行观察性、纵向和前瞻性研究。结果:纳入46例病例,15例新冠肺炎突破性感染病例接种加强针=15天(67%),从加强针到新冠肺炎确诊的时间平均为37天。相对VBE=15天(可以认为加强针已经有效的情况)[1-(疫苗加强针<15天的情况)/(疫苗加强剂>=15天的病例)x100]为60%。接种加强针的新冠肺炎病例=15天。研究结果表明,15天内接受加强针对有症状的新冠肺炎的SARS-CoV-2感染提供了60%的早期保护。然而,这一结果似乎不符合逻辑:这种较低的早期风险可能是短暂的,是由于“接种疫苗的偏见”
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信